Oncology
2 drugs are in development for Intrahepatic Cholangiocarcinoma.
- Companies
- 2
- Clinical trials
- 12
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Intrahepatic Cholangiocarcinoma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| kin-3248 | KINNATE BIOPHARMA INC. (KNTE) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| certepetide | LISATA THERAPEUTICS, INC. (LSTA) |
About this indication
Intrahepatic Cholangiocarcinoma context
Oncology·MeSH: Cholangiocarcinoma (D018281)
Narrower concept of MeSH descriptor Cholangiocarcinoma
Prevalence
2.5 / 100K
Incidence
1.3 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Intrahepatic Cholangiocarcinoma?
BioSniper tracks 2 drugs in development for Intrahepatic Cholangiocarcinoma across 2 companies.
How many clinical trials target Intrahepatic Cholangiocarcinoma?
There are 12 clinical trials targeting Intrahepatic Cholangiocarcinoma tracked by BioSniper.
What is the prevalence of Intrahepatic Cholangiocarcinoma?
The estimated prevalence of Intrahepatic Cholangiocarcinoma is approximately 2.5 per 100,000 population.